PRAKASH MASAND to Schizophrenia
This is a "connection" page, showing publications PRAKASH MASAND has written about Schizophrenia.
Connection Strength
1.713
-
Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting. Ann Clin Psychiatry. 2017 05; 29(2):92-107.
Score: 0.461
-
Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data. Schizophr Res. 2011 Mar; 126(1-3):174-83.
Score: 0.297
-
Differential pharmacology of atypical antipsychotics: clinical implications. Am J Health Syst Pharm. 2007 Jan 15; 64(2 Suppl 1):S3-8; quiz S24-5.
Score: 0.226
-
Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol. 2006 Jan; 1(1):47-56.
Score: 0.210
-
Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization. CNS Spectr. 2005 Oct; 10(10):suppl14 1-15.
Score: 0.207
-
Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison. Int Clin Psychopharmacol. 2017 09; 32(5):235-248.
Score: 0.118
-
Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics. Clin Neuropharmacol. 2013 Nov-Dec; 36(6):223-38.
Score: 0.091
-
Polypharmacy in pregnant women with major psychiatric illness: a pilot study. J Psychiatr Pract. 2007 Nov; 13(6):385-92.
Score: 0.060
-
Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Drugs Aging. 2003; 20(15):1099-110.
Score: 0.043